EP Patent

EP0237289A3 — Pyrazolo [3,4-d] pyrimidine derivatives, their production and use

Assigned to Takeda Pharmaceutical Co Ltd · Expires 1988-07-27 · 38y expired

What this patent protects

Novel pyrazola[3,4-d]pyrimidine derivatives represented by the formula (I) wherein R¹ is an aryl or heteroaryl group which may be substi­ tuted; R² is a lower alkyl group; R³ and R⁴ are independently hydrogen or a lower alkyl group; R⁵ is hydrogen, a lower alkyl g…

USPTO Abstract

Novel pyrazola[3,4-d]pyrimidine derivatives represented by the formula (I) wherein R¹ is an aryl or heteroaryl group which may be substi­ tuted; R² is a lower alkyl group; R³ and R⁴ are independently hydrogen or a lower alkyl group; R⁵ is hydrogen, a lower alkyl group or a lower acyl group, the group R⁵ being attached at the 1- or 2- position of the pyrazole ring; Xis a lower alkylene group which may contain a hetero-atom; and the dotted line designates the presence of two double bonds in the pyrazole ring and their salts activate cerebral functions and metabolisms.

Drugs covered by this patent

Patent Metadata

Patent number
EP0237289A3
Jurisdiction
EP
Classification
Expires
1988-07-27
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.